Sökning: WFRF:(Bucelli Robert) >
Design of a randomi...
Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers : the Atlas study
-
- Benatar, Michael (författare)
- Department of Neurology, University of Miami, FL, Miami, United States
-
- Wuu, Joanne (författare)
- Department of Neurology, University of Miami, FL, Miami, United States
-
- Andersen, Peter M., 1962- (författare)
- Umeå universitet,Neurovetenskaper
-
visa fler...
-
- Bucelli, Robert C. (författare)
- Washington University School of Medicine, MO, St. Louis, United States
-
- Andrews, Jinsy A. (författare)
- The Neurological Institute, Columbia University Irving Medical Center, NY, New York, United States
-
- Otto, Markus (författare)
- Department of Neurology, Martin Luther University, Halle-Wittenberg, Halle (Saale), Germany
-
- Farahany, Nita A. (författare)
- Duke University School of Law, NC, Durham, United States
-
- Harrington, Elizabeth A. (författare)
- Columbia University Irving Medical Center, NY, New York, United States
-
- Chen, Weiping (författare)
- Biogen, MA, Cambridge, United States
-
- Mitchell, Adele A. (författare)
- Biogen, MA, Cambridge, United States
-
- Ferguson, Toby (författare)
- Biogen, MA, Cambridge, United States
-
- Chew, Sheena (författare)
- Biogen, MA, Cambridge, United States
-
- Gedney, Liz (författare)
- Biogen, MA, Cambridge, United States
-
- Oakley, Sue (författare)
- Biogen, MA, Cambridge, United States
-
- Heo, Jeong (författare)
- Biogen, MA, Cambridge, United States
-
- Chary, Sowmya (författare)
- Biogen, MA, Cambridge, United States
-
- Fanning, Laura (författare)
- Biogen, MA, Cambridge, United States
-
- Graham, Danielle (författare)
- Biogen, MA, Cambridge, United States
-
- Sun, Peng (författare)
- Biogen, MA, Cambridge, United States
-
- Liu, Yingying (författare)
- Biogen, MA, Cambridge, United States
-
- Wong, Janice (författare)
- Biogen, MA, Cambridge, United States
-
- Fradette, Stephanie (författare)
- Biogen, MA, Cambridge, United States
-
visa färre...
-
(creator_code:org_t)
- 2022-05-18
- 2022
- Engelska.
-
Ingår i: Neurotherapeutics. - : Springer. - 1933-7213 .- 1878-7479. ; 19, s. 1248-1258
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://umu.diva-por... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Despite extensive research, amyotrophic lateral sclerosis (ALS) remains a progressive and invariably fatal neurodegenerative disease. Limited knowledge of the underlying causes of ALS has made it difficult to target upstream biological mechanisms of disease, and therapeutic interventions are usually administered relatively late in the course of disease. Genetic forms of ALS offer a unique opportunity for therapeutic development, as genetic associations may reveal potential insights into disease etiology. Genetic ALS may also be amenable to investigating earlier intervention given the possibility of identifying clinically presymptomatic, at-risk individuals with causative genetic variants. There is increasing evidence for a presymptomatic phase of ALS, with biomarker data from the Pre-Symptomatic Familial ALS (Pre-fALS) study showing that an elevation in blood neurofilament light chain (NfL) precedes phenoconversion to clinically manifest disease. Tofersen is an investigational antisense oligonucleotide designed to reduce synthesis of superoxide dismutase 1 (SOD1) protein through degradation of SOD1 mRNA. Informed by Pre-fALS and the tofersen clinical development program, the ATLAS study (NCT04856982) is designed to evaluate the impact of initiating tofersen in presymptomatic carriers of SOD1 variants associated with high or complete penetrance and rapid disease progression who also have biomarker evidence of disease activity (elevated plasma NfL). The ATLAS study will investigate whether tofersen can delay the emergence of clinically manifest ALS. To our knowledge, ATLAS is the first interventional trial in presymptomatic ALS and has the potential to yield important insights into the design and conduct of presymptomatic trials, identification, and monitoring of at-risk individuals, and future treatment paradigms in ALS.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)
Nyckelord
- Genetic testing
- Neurofilament
- Phenoconversion
- Pre-fALS
- SOD1-ALS
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Benatar, Michael
-
Wuu, Joanne
-
Andersen, Peter ...
-
Bucelli, Robert ...
-
Andrews, Jinsy A ...
-
Otto, Markus
-
visa fler...
-
Farahany, Nita A ...
-
Harrington, Eliz ...
-
Chen, Weiping
-
Mitchell, Adele ...
-
Ferguson, Toby
-
Chew, Sheena
-
Gedney, Liz
-
Oakley, Sue
-
Heo, Jeong
-
Chary, Sowmya
-
Fanning, Laura
-
Graham, Danielle
-
Sun, Peng
-
Liu, Yingying
-
Wong, Janice
-
Fradette, Stepha ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Neurovetenskaper
- Artiklar i publikationen
-
Neurotherapeutic ...
- Av lärosätet
-
Umeå universitet